{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:07:43Z","timestamp":1771459663038,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>With the discovery of the variant c.577del in the <jats:italic>EPO<\/jats:italic> gene, the procedure for detecting the presence of recombinant erythropoietin (rEPO) has become complicated and time\u2010consuming. To address this situation, an rEPO confirmation method that uses reverse\u2010normal immunopurification coupled with western blotting (WB) and sodium <jats:italic>N<\/jats:italic>\u2010lauroylsarcosinate polyacrylamide gel electrophoresis (SAR\u2010PAGE), which can detect the EPO variant (VAR\u2010EPO) and rEPO with anti\u2010VAR\u2010EPO and anti\u2010EPO antibodies, has been developed. Therefore, it is necessary to develop an internal standard (IS) that can be recognized by an anti\u2010VAR\u2010EPO antibody to monitor reverse immunopurification, ensuring the reliability and accuracy of the analysis. In this study, we constructed an IS based on VAR\u2010EPO modified with polyethylene glycol (PEG) and then assessed its reliability and applicability in doping analysis. The data provided here show that the obtained PEGylated VAR\u2010EPO can be used as an IS to monitor the detection of not only rEPO and VAR\u2010EPO but also EPO receptor agonists in urine samples.<\/jats:p>","DOI":"10.1002\/dta.3836","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T03:55:17Z","timestamp":1733370917000},"page":"1294-1302","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Study on Internal Standards Applicable to the Detection of Recombinant Erythropoietin"],"prefix":"10.1002","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3922-7282","authenticated-orcid":false,"given":"Chengshuai","family":"Niu","sequence":"first","affiliation":[{"name":"School of Sport Science Beijing Sport University  Beijing China"},{"name":"Beijing Anti\u2010Doping Laboratory Beijing Sport University  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaifeng","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Sport Science Beijing Sport University  Beijing China"},{"name":"Beijing Anti\u2010Doping Laboratory Beijing Sport University  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinchao","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Anti\u2010Doping Laboratory Beijing Sport University  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5451-1144","authenticated-orcid":false,"given":"Sen","family":"He","sequence":"additional","affiliation":[{"name":"Beijing Anti\u2010Doping Laboratory Beijing Sport University  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-5358","authenticated-orcid":false,"given":"Xinmiao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Beijing Anti\u2010Doping Laboratory Beijing Sport University  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.06.030"},{"issue":"3","key":"e_1_2_8_3_1","first-page":"281","article-title":"To Give or Not to Give Recombinant EPO to Anemia Endangered Cancer Patients","volume":"107","author":"Sulkowska M.","year":"2006","journal-title":"Prague Medical Report"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2863"},{"key":"e_1_2_8_5_1","unstructured":"WADA \u201cList of Prohibited Substances and Methods 2024\u201d accessed June 02 2024 https:\/\/www.wada\u2010ama.org\/en\/resources\/world\u2010anti\u2010doping\u2010code\u2010and\u2010international\u2010standards\/prohibited\u2010list."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/elps.200600363"},{"key":"e_1_2_8_7_1","unstructured":"WADA \u201cWADA technical document\u2010TD2024 EPO \u201d (2024) accessed Jun 02 2024 https:\/\/www.wada\u2010ama.org\/en\/resources\/lab\u2010documents\/td2024epo."},{"key":"e_1_2_8_8_1","first-page":"251","volume-title":"Handbook of Experimental Pharmacology","author":"Reichel C.","year":"2010"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0134(199705)28:1<94::AID-PROT9>3.0.CO;2-J"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2989"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3200"},{"key":"e_1_2_8_12_1","unstructured":"X.Zhou S.He C.Niu et\u00a0al. \u201cDevelopment of Confirmation Method for Recombinant EPO Using Reverse\u2010Normal Immunopurification Coupled With Western Blotting \u201d The 41st Manfred Donike Workshop on Doping Analysis. Cologne. (2024)."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.201901340"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105063"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3211"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13361-016-1359-3"},{"key":"e_1_2_8_17_1","unstructured":"Thermo Fisher Scientific \u201cMS (PEG)n Reagents \u201d (2024) accessed June 02 2024 https:\/\/assets.thermofisher.cn\/TFS\u2010Assets%2FLSG%2Fmanuals%2FMAN0016373_2161767_MS_PEG_n_Reagents_UG.pdf."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-2697(02)00407-4"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1915"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2703"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:42:54Z","timestamp":1760380974000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.3836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/dta.3836"],"URL":"https:\/\/doi.org\/10.1002\/dta.3836","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"2024-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}